Lurati Alfredomaria, Marrazza Mariagrazia, Angela Katia, Scarpellini Magda
Fornaroli Hospital, Rheumatology Unit, Magenta, Italy.
Biologics. 2010 Feb 4;4:1-4.
To report side effects seen in a clinical cohort of patients aged >65 years with rheumatoid arthritis (RA) treated with the tumor necrosis factor-alpha TNF-alpha blocker etanercept and to compare the side effects rate with patients aged </=65 years.
All patients with RA that started etanercept and who were referred to our rheumatology unit from November 2005 to March 2009 were included in this study and prospectively followed to collect side effects related to therapy.
ONE HUNDRED THREE PATIENTS WERE ENROLLED: 41 (37 females, 4 males) aged >65 years and 62 (40 females, 22 males) aged <65 years. In the patients aged >65 years, the safety profile (defined as rate of side effects) of etanercept was similar to that in patients aged </=65 years (P > 0.05) and the survival curves between the groups were similar (P > 0.05).
In our three-year experience, the anti-TNFalpha agent etanercept has been well tolerated and safe in elderly patients. The risk of side effects in these patients was no greater than in subjects aged </=65 years. However, such inhibitors are associated with various and numerous side effects and elderly patients with RA should be carefully monitored to limit the risk of side effects during anti-TNFalpha therapy as much as possible.
报告年龄大于65岁的类风湿关节炎（RA）患者临床队列中使用肿瘤坏死因子-α（TNF-α）阻滞剂依那西普治疗时出现的副作用，并将副作用发生率与年龄小于或等于65岁的患者进行比较。
本研究纳入了2005年11月至2009年3月开始使用依那西普并转诊至我们风湿病科的所有RA患者，并对其进行前瞻性随访以收集与治疗相关的副作用。
共纳入103例患者：年龄大于65岁的41例（37例女性，4例男性），年龄小于65岁的62例（40例女性，22例男性）。年龄大于65岁的患者中，依那西普的安全性概况（定义为副作用发生率）与年龄小于或等于65岁的患者相似（P>0.05），两组间的生存曲线也相似（P>0.05）。
根据我们三年的经验，抗TNFα药物依那西普在老年患者中耐受性良好且安全。这些患者的副作用风险并不高于年龄小于或等于65岁的患者。然而，此类抑制剂会引发多种副作用，RA老年患者应接受仔细监测，以尽可能降低抗TNFα治疗期间的副作用风险。
Zotero 插件